Objective: To evaluate the association between peripheral inflammatory biomarkers and the incidence of Parkinson’s disease.
Background: Parkinson’s disease is a progressive neurodegenerative disorder in which growing evidence suggests a key role for systemic inflammation in its pathogenesis. Peripheral inflammatory biomarkers derived from routine blood tests have emerged as potential predictors of disease risk and progression.
Method: In accordance with the PRISMA guidelines, major electronic databases including PubMed, Embase, Web of Science, and Cochrane Library were searched up to February 2026 for studies assessing the association between inflammatory biomarkers and PD incidence. Random-effects models were used to calculate pooled odds ratio (OR) with 95% confidence interval (CI). Outcomes included NLR (neutrophil-to-lymphocyte ratio), SII (systemic immune-inflammation index), SIRI (systemic inflammatory response index), CRP (C-reactive protein), PLR (platelet-to-lymphocyte ratio), LMR (lymphocyte-to-monocyte ratio), lymphocyte count, and neutrophil count.
Results: A total of 15 studies involving 279,935 participants were analysed. Higher NLR (OR 1.31, 95% CI 1.09–1.57), SII (OR 1.22, 95% CI 1.03–1.45), and SIRI (OR 1.17, 95% CI 1.06–1.29) were significantly associated with increased Parkinson’s disease incidence. Conversely, LMR (OR 0.79, 95% CI 0.71–0.87) and lymphocyte levels (OR 0.71, 95% CI 0.65–0.79) showed a significant inverse association with disease risk. No significant associations were observed for CRP (OR 1.05, 95% CI 0.91–1.22), PLR (OR 1.27, 95% CI 0.82–1.95), or neutrophil count (OR 1.11, 95% CI 0.97–1.27).
Conclusion: Systemic inflammatory markers, particularly NLR, SII, and SIRI, are associated with an increased risk of Parkinson’s disease, while higher LMR and lymphocyte levels appear protective. These findings suggest that readily available inflammatory indices may serve as simple and cost-effective predictors to support early risk assessment for Parkinson’s disease. Further prospective studies are needed to validate their predictive utility.
To cite this abstract in AMA style:
H. Hussien, A. Hegazi, A. Elsaid. Peripheral Inflammatory Biomarkers as Predictive Indicator for Parkinson’s Disease: a Systematic Review and Meta-Analysis [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/peripheral-inflammatory-biomarkers-as-predictive-indicator-for-parkinsons-disease-a-systematic-review-and-meta-analysis/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/peripheral-inflammatory-biomarkers-as-predictive-indicator-for-parkinsons-disease-a-systematic-review-and-meta-analysis/